Dennis Slamon ONCOLOGY Professor of Medicine; Chief, Division of Hematology/Oncology; Associate Director of ...

Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment between 2015 ...

As previously presented at the 2025 European Society for Medical Oncology (ESMO) Annual Congress, the combination ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...

This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...

Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, ...

Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

January 2026 The National Foundation for Cancer Research mourns the loss of Dr. Brian Leyland-Jones, a leading figure in global cancer research, a tireless patient advocate, and a cherished member of ...

Group results In 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 61.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc ...

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive ...

Cancer patients receiving their medication at leading referral hospitals across the country have been frequently experiencing ...